arginylproline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

arginylproline: first & second amino acid in substance P sequence; RN given refers to (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Arg-Pro : A dipeptide obtained by formal condensation of the carboxy group of L-arginine with the amino group of L-proline. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID Source	ID
PubMed CID	151003
CHEMBL ID	48223
CHEBI ID	141419
SCHEMBL ID	1674799
MeSH ID	M0117892

Synonyms (21)

Synonym
bdbm50049715
arginylproline
CHEMBL48223 ,
(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxylic acid
rp dipeptide
arginine proline dipeptide
(2s)-1-[(2s)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carboxylic acid
l-arginyl-l-proline
l-proline, 1-l-arginyl-
r-p dipeptide
2418-69-1
arg-pro
arginine-proline
arginine-proline dipeptide
CHEBI:141419
h-arg-pro-oh
SCHEMBL1674799
DTXSID70178886
AKOS030622984
arginyl-proline
h-arg-pro-oh sulfate salt

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
dipeptide	Any molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay ID	Title	Year	Journal	Article
AID1183271	Inhibition of ACE (unknown origin)	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	CoMFA and CoMSIA analysis of ACE-inhibitory, antimicrobial and bitter-tasting peptides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (12.50)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (12.50)	29.6817
2010's	4 (50.00)	24.3611
2020's	2 (25.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.68 (24.57)
Research Supply Index	2.40 (2.92)
Research Growth Index	5.08 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.68)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (11.11%)	5.53%
Reviews	1 (11.11%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	1 (11.11%)	0.25%
Other	6 (66.67%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
substance p [no description available]	1.96	1	0	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
leucyltyrosine leucyltyrosine: RN given refers to L-Tyr,L-Leu-isomer; RN for cpd without isomeric designation not avail 4/93	2.1	1	0	dipeptide	metabolite
alanylproline alanylproline: RN given refers to all (L)-isomer	2.1	1	0	dipeptide zwitterion; dipeptide	metabolite
glycyltryptophan glycyltryptophan: RN given refers to (L)-isomer. Gly-Trp : A dipeptide formed from glycine and L-tryptophan residues.	2.1	1	0	dipeptide	metabolite
glycyltyrosine Gly-Tyr : A dipeptide composed of glycine and L-tyrosine joined by a peptide linkage.	2.1	1	0	dipeptide	metabolite
alanyltyrosine alanyltyrosine: tyrosine source; RN given refers to (L)-isomer. Ala-Tyr : A dipeptide composed of L-alanine and L-tyrosine joined by a peptide linkage.	2.1	1	0	dipeptide	metabolite
glycyl-l-phenylalanine glycylphenylalanine: RN given refers to (DL)-isomer. Gly-Phe : A dipeptide formed from glycine and L-phenylalanine residues.	2.1	1	0	dipeptide zwitterion; dipeptide	human metabolite; metabolite
aspartyl-phenylalanine aspartyl-phenylalanine: metabolite of aspartame; may inhibit angiotensin converting enzyme; RN given refers to all (L)-isomer	2.1	1	0	dipeptide	human blood serum metabolite; human xenobiotic metabolite
alanylphenylalanine alanylphenylalanine: RN given refers to (L-Ala-L-PheAla)-isomer	2.1	1	0	dipeptide	metabolite
proline Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.	2.6	1	0	amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid	algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
arginylarginine Arg-Arg : A dipeptide formed from two L-arginine residues.	3.86	2	1	dipeptide	Mycoplasma genitalium metabolite
n-valyltryptophan N-valyltryptophan: RN given refers to (L)-isomer	2.1	1	0	peptide
lysylproline lysylproline: third & fourth amino acid in substance P sequence. Lys-Pro : A dipeptide formed from L-lysine and L-proline residues.	2.4	2	0	dipeptide	metabolite
oleic acid Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.	2.6	1	0	octadec-9-enoic acid	antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent
Phe-Tyr Phe-Tyr : A dipeptide formed from L-phenylalanine and L-tyrosine residues.	2.1	1	0	dipeptide	metabolite
glycylproline Gly-Pro : A dipeptide consisting of L-proline having a glycyl residue attached to its alpha-amino group.	2.1	1	0	dipeptide zwitterion; dipeptide	metabolite
methionyltryptophan Met-Trp : A dipeptide formed from L-methionine and L-tryptophan residues.	2.1	1	0	dipeptide	metabolite
phenylalanyl-valine Val-Phe : A dipeptide formed from L-valine and L-phenylalanine residues.	2.1	1	0	dipeptide	metabolite
valyltyrosine valyltyrosine: from sardine muscle hydrolyzate. Val-Tyr : A dipeptide formed from L-valine and L-tyrosine residues.	2.1	1	0	dipeptide	metabolite
phenylalanylproline Phe-Pro : A dipeptide formed from L-phenylalanine and L-proline residues.	2.1	1	0	dipeptide	metabolite
isoleucyl-tyrosine isoleucyl-tyrosine: a dipeptide with antihypertensive effect. Ile-Tyr : A dipeptide formed from L-isoleucine and L-tyrosine residues.	2.1	1	0	dipeptide	metabolite
prolylvaline Val-Pro : A dipeptide formed from L-valine and L-proline residues.	2.1	1	0	dipeptide	metabolite
prolyl-proline Pro-Pro : A dipeptide formed from two L-proline residues.	3.63	2	0	dipeptide	human urinary metabolite; Mycoplasma genitalium metabolite

Condition	Relationship Strength	Studies	Trials
Fatty Liver, Nonalcoholic [description not available]	3.52	4	0
Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION.	3.52	4	0
Disease Exacerbation [description not available]	2.31	1	0
Microsatellite Instability The occurrence of highly polymorphic mono- and dinucleotide MICROSATELLITE REPEATS in somatic cells. It is a form of genome instability associated with defects in DNA MISMATCH REPAIR.	2.31	1	0
Bladder Cancer [description not available]	2.31	1	0
Local Neoplasm Recurrence [description not available]	2.31	1	0
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	2.31	1	0
Genetic Predisposition [description not available]	3.45	2	0
B-Cell Chronic Lymphocytic Leukemia [description not available]	2.21	1	0
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	2.21	1	0
Cancer of Mouth [description not available]	3	1	0
Mouth Neoplasms Tumors or cancer of the MOUTH.	3	1	0
Acute Brain Injuries [description not available]	3.41	1	1
Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.	3.41	1	1

chemdatabank.com